LABORATORY CORPORATION ($NYSE:LH) announced its financial results for the second quarter of FY2023, as of June 30 2023, on July 27 2023. Total revenue had decreased by 17.9%, amounting to USD 3033.7 million, compared to the same period in the previous year. Additionally, net income had declined by 47.3% to USD 188.9 million.
The stock opened at $215.1 and closed at $216.0, representing a 1.3% decrease from its last closing price of $218.8. On the back of strong financial performance in the first half of the year, LABORATORY CORPORATION‘s outlook for the rest of the year looks promising. The company’s long-term prospects remain strong as it continues to focus on customer satisfaction and innovation in laboratory services. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Laboratory Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Laboratory Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Laboratory Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Laboratory Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Laboratory Corporation Intrinsic Value Calculation
We at GoodWhale have taken a close look at the wellbeing of LABORATORY CORPORATION and have come to the conclusion that the fair value of their share is around $215.9. This figure has been calculated using our proprietary Valuation Line, which takes into account historical performance as well as the outlook for the company. We can see that the current stock price of LABORATORY CORPORATION is $216.0, which is an indication that the company is trading at a fair price. This means that investors are likely getting a good value for their money, as this stock is neither over- nor undervalued. More…
Risk Rating Analysis
Star Chart Analysis
In the medical laboratory testing industry, Laboratory Corp of America Holdings (LabCorp) competes with several other large companies, including Charles River Laboratories International Inc, Beijing Strong Biotechnologies Inc, and Eurofins Scientific SE. While each company has its own strengths and weaknesses, LabCorp has been able to maintain a leading position in the industry through its strong focus on customer service and innovative product offerings.
– Charles River Laboratories International Inc ($NYSE:CRL)
Founded in 1948, Charles River Laboratories International, Inc. is a global provider of drug discovery, development and manufacturing services. The company operates in three segments: Research Models and Services (RMS), Laboratory Services (LS) and Manufacturing Support (MS). It serves pharmaceutical and biotechnology companies, government agencies and academic institutions around the world.
The company has a market cap of $10.15 billion and a return on equity of 13.86%. Charles River Laboratories International, Inc. is a global leader in providing drug discovery, development and manufacturing services. The company serves pharmaceutical and biotechnology companies, government agencies and academic institutions around the world.
– Beijing Strong Biotechnologies Inc ($SZSE:300406)
As of 2022, Beijing Strong Biotechnologies Inc has a market cap of 10.38B and a Return on Equity of 9.89%. The company is engaged in the research, development, production and marketing of biopharmaceutical products. Its products include vaccines, antibodies, blood products and other therapeutics.
– Eurofins Scientific SE ($LTS:0MV5)
Eurofins Scientific SE is a global leader in the food, environmental, pharmaceutical and cosmetics industries. With a market cap of 11.83B as of 2022 and a Return on Equity of 12.32%, the company is well-positioned to continue its growth and expansion in these industries. As a company that provides testing, analysis, and scientific support services to its clients, Eurofins Scientific is dedicated to ensuring the safety and quality of the products and services it provides. In addition to its commitment to quality, the company is also committed to the environment and to the communities in which it operates.
LABORATORY CORPORATION reported its financial results for the second quarter of FY2023, with total revenue of USD 3033.7 million and a net income of USD 188.9 million. Compared to the same period last year, the total revenue decreased by 17.9%, while net income declined by 47.3%. This suggests that overall performance of the company has weakened during this period. As such, investors should be cautious when investing in the company and carefully assess market trends and potential risks before making any decisions.